LifeMD, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LFMD research report →
Range $5 – $9
Price Chart
About the company
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more.
- CEO
- Justin Schreiber
- IPO
- 2008
- Employees
- 350
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on LFMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $69.84M
- P/E
- -3.08
- PEG
- 0.03
- P/S
- 0.41
- P/B
- -132.58
- EV/EBITDA
- -4.54
- Div Yield
- 0.00%
- Gross Margin
- 84.31%
- Op Margin
- -11.44%
- Net Margin
- -11.60%
- ROE
- -192.39%
- ROIC
- -410.14%
Latest fiscal year · YoY change
- Revenue
- $194.06M-8.7%
- Gross Profit
- $154.76M-17.8%
- Op Income
- $-7,669,694
- Net Income
- $-7,106,359+62.4%
- EPS
- $-0.23+56.6%
- OCF Growth
- -52.7%
- FCF Growth
- -120.7%
- 52W High
- $5.38
- 52W Low
- $1.38
- 50D MA
- $2.50
- 200D MA
- $3.56
- Beta
- 2.16
- RSI (14)
- 33
- Avg Volume
- 911.04K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LifeMD reported third-quarter revenue below guidance, but management emphasized improving unit economics, a ramp in branded GLP-1 pharmacy fulfillment, and a lower-cost enterprise growth channel as it reset 2026 expectations lower.· November 12, 2026
- Revenue was $44.6 million, below the guided range of $48 million to $51 million, and down about 7% from $47.7 million a year ago.
- Adjusted EBITDA was nearly breakeven at a $0.4 million loss, while gross profit was $36.4 million and gross margin was about 82% versus 85% a year ago.
- The company reset 2026 outlook to revenue of $188 million to $191 million and adjusted EBITDA of negative $12.6 million to negative $10.6 million, with a year-end run-rate now expected around $200 million instead of $250 million.
- Management said the shortfall reflected later-than-expected branded GLP-1 fulfillment, a deliberate reduction in marketing spend, and weaker-than-expected performance from some earlier patient cohorts.
- LifeMD highlighted new branded drug arrangements with Eli Lilly and Novo Nordisk, the AT&T enterprise launch, and plans to roll out new pharmacy products and patient-experience upgrades in early 2027.
Third-quarter revenue was $44.6 million, down approximately 7% from $47.7 million in the prior-year period and below guidance of $48 million to $51 million. Gross profit was $36.4 million versus $40.7 million a year ago; gross margin was approximately 82% versus 85% a year ago and 89% in the second quarter, with management saying the decline was mainly due to gross-basis revenue presentation on branded pharmaceutical arrangements rather than weaker economics. GAAP net loss from continuing operations attributable to common stockholders was $5.2 million, or $0.11 per share, versus $7.9 million, or $0.16 per share in the second quarter. Adjusted EBITDA was a $0.4 million loss, within guidance, and improved by $3.1 million versus the second quarter. Active subscribers were approximately 350,000, up 13% year over year and nearly flat sequentially. For Q4, management guided to revenue of $46 million to $49 million and adjusted EBITDA of negative $4 million to negative $2 million. Full-year 2026 guidance was cut to revenue of $188 million to $191 million and adjusted EBITDA of negative $12.6 million to negative $10.6 million, versus prior guidance of $205.5 million to $212.5 million and negative $6 million to breakeven.
Justin Schreiber framed the quarter as a strategic transition period rather than a demand problem, saying the company is now more confident in its branded GLP-1 strategy and in owning the patient experience through its pharmacy. He emphasized the AT&T partnership, the pharmacy’s momentum, and a forthcoming product/technology overhaul as key future growth drivers. His tone was optimistic and directional, but he repeatedly acknowledged that recent softness, timing delays, and a cautious marketing posture weighed on near-term results.
Atul Kavthekar focused on the financial reset and the mechanics behind it. He said revenue was $44.6 million, gross profit was $36.4 million, gross margin was 82%, S&M expense was $18.5 million down $9.5 million sequentially and 18% year over year, G&A was $14.7 million, and adjusted EBITDA was a $0.4 million loss. He also noted $21.9 million in cash, no debt at quarter end, and a subsequent $12.5 million non-convertible senior secured term loan with Avenue Capital to better support working capital needs as branded drug fulfillment scales.
Analysts focused on what will drive revenue reacceleration, how branded GLP-1 gross-basis accounting affects margins and working capital, and whether the marketing pullback signaled weaker demand. Management said the main near-term drivers are improved unit economics, branded GLP-1 launches, enterprise growth through AT&T and other partnerships, and pharmacy expansion; they also said 2027 guidance will be issued in early Q1. On margins, management said gross margin should compress as gross-basis branded fulfillment grows, with Justin suggesting the blended overall margin could settle in the mid- to low-60s and potentially high-50s by the end of 2027, while gross profit dollars should rise. They also said the AT&T/enterprise program will be rolled out in waves, and specific partnership timing was not disclosed.
The company said it has now secured arrangements with both Eli Lilly and Novo Nordisk, enabling branded GLP-1 fulfillment through its own pharmacy, which management views as a major strategic advantage. It also pointed to stronger unit economics, lower customer acquisition cost, a growing pharmacy business, and an enterprise channel that could bring in patients at much lower acquisition cost than paid media.
Near-term results were weaker than expected, and management cut full-year revenue and EBITDA guidance materially while reducing the year-end revenue run-rate target to about $200 million from $250 million. Gross margin will likely come down as branded-drug fulfillment grows on a gross basis, and management also said the timing of enterprise partnerships, new pharmacy products, and some branded launches remains uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.3%
- Shares Outstanding
- 48.33M
- Float Shares
- 39.79M
of shares held by institutions
124 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Federated Hermes, Inc. | 4.05M | ▲ 1.30M |
| Blackrock, Inc. | 3.02M | ▼ 14.36K |
| Vanguard Group Inc | 2.02M | ▼ 205.17K |
| Vanguard Capital Management LLC | 1.72M | ▼ 16.33K |
| State Street Corp | 1.29M | ▼ 30.44K |
| Geode Capital Management, LLC | 1.07M | ▼ 1.07K |
| Renaissance Technologies LLC | 990.73K | ▼ 88.80K |
| Prescott Group Capital Management, L.L.C. | 897.22K | 0 |
| Marshall Wace, Llp | 809.14K | ▲ 251.66K |
| Brc Group Holdings, Inc. | 637.32K | ▼ 234.26K |
| Aqr Capital Management LLC | 619.51K | ▲ 421.18K |
| Susquehanna International Group, Llp | 478.28K | ▲ 13.08K |
Held by 127 ETFs
Biggest fund positions in LFMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 26 | LAROVERE JOAN | other | 35,000 |
| Aug 11, 26 | Strawn John R Jr | other | 35,000 |
| May 4, 26 | Strawn John R Jr | other | 50,000 |
| Aug 11, 26 | DiTrolio Joseph | other | 35,000 |
| Dec 2, 24 | Simon Roberto | other | 24,648 |
| Dec 2, 24 | Simon Roberto | other | 6,162 |
| Dec 2, 24 | Simon Roberto | other | 50,000 |
| Aug 11, 26 | Simon Roberto | other | 35,000 |
| May 4, 26 | Simon Roberto | other | 50,000 |
| Aug 11, 26 | MACRAE CALUM ARCHIBALD | other | 35,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LFMD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on LFMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
LifeMD: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 14
LifeMD, Inc. (LFMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
LifeMD, Inc. (LFMD) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 12
What LifeMD (LFMD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
LifeMD Reports Third Quarter 2026 Results
globenewswire.com · Nov 12
Lost Money on LifeMD, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 14.56% Share Price Drop
businesswire.com · Nov 10
Did You Lose Money on LifeMD, Inc. Stock? The Law Offices of Howard G.
businesswire.com · Nov 10
Lost Money on LifeMD, Inc. Shares? The Law Offices of Frank R.
businesswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
